bmiMD review

The $99/month injection headline requires $594 for six months upfront. The injection tiles reviewed in October 2026 list $139 for one month and $357 for three, but separate process copy calls $139/month quarterly billed. That conflict leaves the selected term needing confirmation. Sermorelin tablets have a separate ladder: $129 monthly, $327 for three months or $534 for six. NAD+ injection lists $159 monthly, $447 for three months, $774 for six and $1,428 for twelve. Do not mix products or assume their lowest rates are monthly payments.

The injection listing describes a 5 mL vial at 2 mg/mL, totaling 10 mg, with a subcutaneous injection kit and free subscription shipping. That identifies advertised vial content but does not establish your prescribed treatment duration or personal dose. Monthly delivery language does not settle how many treatment days a particular order covers. Ask for the actual formulation, quantity, supplies and clinician's instructions; tablet and injectable routes should not be assumed equivalent.

The product FAQ says no cancellation fees, while the reviewed refund policy imposes a $100 fee after intake submission. The policy also requires a pause or cancellation at least seven days before renewal, with the deadline shown in the portal. Clarify the applicable fee and next processing date before committing. Canceling renewal and recovering money already paid are separate questions; a cancellation confirmation does not itself promise a refund for the current prepaid term.

Ordinary prepaid plans generally become nonrefundable once the initial order goes to the pharmacy. Turning off renewal leaves the current term in place. The reviewed policy separately allows a documented medical cancellation to qualify for credit or a refund less completed shipments. That exception does not promise a full refund whenever a patient chooses to stop. Before prepaying, ask what documentation is required and how completed shipments affect any remaining credit or refund.

The reviewed pages do not establish a universal funded lab panel or an allowance of scheduled appointments. Provider messaging for side effects and dose adjustments is advertised, along with 24/7 customer support and clinician access. Those access claims do not guarantee an immediate clinical response. Ask which testing your clinician may request, who pays, how follow-up visits are arranged and when clinical messages are answered. Messaging access does not guarantee a prescription or a particular treatment adjustment.

The reviewed product pages give different coverage claims: sermorelin injection advertises all 50 states, tablets exclude South Carolina, and NAD+ excludes California and South Carolina. These are provider claims, with prescribing and dispensing eligibility still patient-specific. The dispensing facility and its 503A/503B category are not established by the reviewed pages. References to licensed sterile compounding pharmacies or testing do not identify the pharmacy assigned to your prescription. Confirm both product eligibility and the actual dispenser before payment.